Results 121 to 130 of about 146,080 (258)

Symptom cluster profiles in adolescents with inflammatory bowel disease: Cross‐sectional study using ImproveCareNow data

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Sleep disturbance, pain, anxiety, depression, and fatigue are prevalent in adolescents and young adults with inflammatory bowel disease (IBD). These symptoms often present in co‐occurring sets, known as symptom clusters. We aimed to identify distinct symptom clusters and factors associated with symptom profiles in adolescents with ...
Caeli Malloy, Kurt Kroenke, Patrick O. Monahan, Susan M. Rawl, Steven J. Steiner, Wendy R. Trueblood Miller, for the ImproveCareNow Pediatric IBD Learning Health System   +6 more
wiley   +1 more source

Multicenter experience using tofacitinib for treatment of refractory pediatric inflammatory bowel diseases in the United States

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Tofacitinib is a selective Janus kinase (JAK‐1) inhibitor approved for the treatment of ulcerative colitis (UC) in adults. Data is limited in the pediatric population. The aim of this study was to evaluate the efficacy of tofacitinib in pediatric inflammatory bowel disease (IBD).
Denise D. Young, Jennifer E. Murphy, Mallory Chavannes, Jennifer L. Dotson, Jeanne Tung, Erica Chang, Brad Pasternak, Erin Crawford, Nancy McGreal, Jonathan Moses, Sandra C. Kim   +10 more
wiley   +1 more source

Efficacy of upadacitinib induction for pediatric inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Objectives Upadacitinib, a second‐generation Janus kinase (JAK) inhibitor, is approved for moderate to severe Crohn's disease (CD) and ulcerative colitis (UC) in adults. Its efficacy in pediatric patients remains unclear, though early reports suggest benefits in refractory inflammatory bowel disease (IBD).
Evan Greenhall, Nina Gautam, Paula Prieto‐Jimenez, Elizabeth Hilow, Ashish Patel, Brad Pasternak   +5 more
wiley   +1 more source

Real‐World, Prospective, Multicenter Outcomes to Brodalumab Treatment in Patients With Moderate‐to‐Severe Psoriasis in Greece (The RESOLVE Study)

JEADV Clinical Practice, EarlyView.
RESOLVE was a prospective, real‐world study in patients with moderate‐to‐severe psoriasis treated with brodalumab. At Week 12, 76.4% achieved PASI ≤ 3, 53.5% PASI100, and 71.5%/54.2% achieved sPGA0/1 and sPGA 0, respectively. At Week 52, 96.1% achieved sPGA success (clear/almost clear). Furthermore, at Week 52, mean DLQI scores decreased by 12.6 ± 6.2,
Electra Nicolaidou, Pantelis Panagakis, Dimitrios Xekardakis, Natalia Rompoti, Marina Papoutsaki, Ioanna Lefaki, Kanella Kalapothakou, Despina Exadactylou, Athanasios Chaniotis, Vasiliki Chasapi, Alexander Stratigos   +10 more
wiley   +1 more source

Clinical Features and Therapeutic Outcomes in Pyoderma Gangrenosum: A Prospective Cohort Study

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis highly associated with systemic comorbidities. Accurate diagnosis and treatment remain challenging due to its rarity and clinical mimickers. Objectives To evaluate demographic, clinical features and treatment outcomes in patients referred with suspected PG at a tertiary ...
David Croitoru, Nesrine Brahimi, Haleh Zabihi, Cathryn Sibbald, Kyle Seigel, Delaram Shojaei, Eric McMullen, Afsaneh Alavi, Lily Archaempong, Aaron M. Drucker, Adam Weizman, Kenneth Croitoru, Robert Inman, Vincent Piguet   +13 more
wiley   +1 more source

Patient Characteristics, Disease Profile and Treatment Patterns in Mild and Moderate Psoriasis Patients: Results From Real‐World Clinical Practices in Five European Countries (PROSPECT Study)

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Categorisation of psoriasis (PsO) disease severity in patients varies, although body surface area (BSA) affected is commonly used (< 3% ‘mild’, 3%–10% ‘moderate’ and > 10% ‘severe’). While moderate‐severe PsO has been well‐studied, more limited information regarding mild‐to‐moderate PsO is available.
Emily Goddard, Aaron Keal, James Hetherington, Sophie Barlow, David Wu, Melany Worbes‐Cerezo, Alexander Litvintchouk   +6 more
wiley   +1 more source

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

JEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender, Rosalind Hughes, Brian Kirby   +2 more
wiley   +1 more source

Prevalence of eunatremic, eukalemic hypoadrenocorticism in dogs with signs of chronic gastrointestinal disease and risk of misdiagnosis after previous glucocorticoid administration

Journal of Veterinary Internal Medicine
Background Dogs with eunatremic, eukalemic hypoadrenocorticism (EEH) typically show signs of chronic gastrointestinal disease (CGD). Previous glucocorticoid administration (PGA) can give false‐positive results on the ACTH stimulation test (ACTHst ...
Antonio Maria Tardo, Francesca Del Baldo, Rodolfo Oliveira Leal, Giorgia Galiazzo, Marco Pietra, Alba Gaspardo, Federico Fracassi   +6 more
doaj   +1 more source

G2‐PASE: A Novel, Rapid, and Reliable Measure of Plaque Psoriasis Severity

JEADV Clinical Practice, EarlyView.
ABSTRACT Background The Psoriasis Area and Severity Index (PASI), a composite measure of plaque psoriasis disease severity, is commonly used to determine treatment eligibility and response, but is time consuming for every‐day clinical use. The Gulliver‐Gestalt‐Psoriasis Area Severity Estimate (G2‐PASE) was developed to approximate PASI scores using ...
Wayne P. Gulliver, Wayne Langholff, Lyn Guenther, Vimal H. Prajapati, Julien Ringuet, Om Prakash Yadav, Susanne R. Gulliver, Steve Fakharzadeh, Kim Parnell Lafferty, Nastaran Abbarin, Robert Gniadecki   +10 more
wiley   +1 more source

The impact of randomized controlled trials on the management of anterior shoulder instability: A bibliometric and altmetrics analysis

Knee Surgery, Sports Traumatology, Arthroscopy, EarlyView.
Abstract Purpose To perform a bibliometric and altmetric analysis of randomized controlled trials (RCTs) in anterior shoulder instability (ASI) management through a citation and altmetrics analysis. Methods A complete search of MEDLINE, EMBASE and CENTRAL databases was conducted from inception to 17 July 2025 for RCTs assessing surgical management of ...
Amr AlMasri, Rohaan Syan, Danielle Dagher, Ashraf Hantouly, Khalid Alkhelaifi, Moin Khan   +5 more
wiley   +1 more source